🚀第 2 天 #ESMO26 上消化道口头摘要，结果汇总
🟢紫杉醇 + tovecimig（对比紫杉醇）在晚期胆道癌（BTC）二线治疗中提高了 ORR 和 PFS
🟢辅助 GemCis 与卡培他滨在胆道癌中，DFS 中位数 2.14 对 1.49 年，log-rank p=0.097
🟣STRIDE ± L + TACE (EMERALD-3)，治疗期间肝功能稳定，无论基线肝功能如何，安全性相当
🟣BGB-B2033（GPC3 × 4-1BB 双特异性抗体）单药治疗晚期 HCC（I 期）：ORR 有希望，进一步开发
#cancer #oncology #MedX #GI #gastrointestinal #biliary #liver #hcc #cholangiocarcinoma @OncoAlert
49 浏览 · 0 赞 · 0 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Erman Akkus · x.com